You just read:

FDA Grants Fanapt® Three Years of Marketing Exclusivity for Labeling Changes Relating to Maintenance Treatment of Schizophrenia

News provided by

Vanda Pharmaceuticals Inc.

Jun 15, 2016, 07:00 ET